Breakthrough Multiple Sclerosis medication is ‘an important step forward’
Those affected by Multiple Sclerosis are set to save $54,000 a year after a ‘breakthrough’ drug was listed on the Pharmaceutical Benefits Scheme (PBS).
From January 1, the Multiple Sclerosis (MS) medication Mavenclad will cost $40.30 a script or $6.50 for concessional patients.
Clinical trials for the drug show MS symptoms dissipated within a month of treatment.
“So for many, this really is a Christmas miracle,” says Michael McLaren.
Federal Health Minister Greg Hunt says “it really is an important step forward”.
“The estimate is that about 6200 Australians will have access to and benefit from Mavenclad,” he tells Michael.
“It is one of these breakthrough medicines.”
The minister says in some cases, there could be a reversal of symptoms.
“It’s not a cure but it’s an incredibly important treatment.”
Click PLAY below to hear the full interview